



Cover fig caption: Aggravation of bone degradation and proteoglycan depletion in murine collagen-induced arthritis in  $\alpha 7$  subunit of nicotinic acetylcholine receptor ( $\alpha 7nAChR$ )-deficient ( $\alpha 7nAChR^{-/-}$ ) mice compared with wild-type (WT) mice ( $n=20$  per group). (A) Representative radiographs of the knee joints of an  $\alpha 7nAChR^{-/-}$  mouse and a WT mouse. p1720.

#### Editor

Tore K Kvien

#### Associate Editors

Francis Berenbaum  
Hans Bijlsma  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

#### Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 8.11

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2010 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Newgen and printed in the UK on acid-free paper from sustainable forests by Latimer Trend, Plymouth

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Mercury International Ltd. Periodicals postage paid at Rahway, NJ, USA. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases* Mercury International Ltd, 365 Blair Road, Avenel NJ 07001, USA.

## Editorial

- 1575** The American College of Rheumatology/ European League Against Rheumatism Criteria for the classification of rheumatoid arthritis: a game changer  
*S Cohen, P Emery*

- 1577** A welcome address for the new criteria  
*D van Schaardenburg, B A C Dijkmans*

## Criteria

- 1580** 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative  
*D Aletaha, T Neogi, A J Silman, J Funovits, D T Felson, C O Bingham III, N S Birnbaum, G R Burmester, V P Bykerk, M D Cohen, B Combe, K H Costenbader, M Dougados, P Emery, G Ferraccioli, J M W Hazes, K Hobbs, T W J Huizinga, A Kavanaugh, J Kay, T K Kvien, T Laing, P Mease, H A Ménard, L W Moreland, R L Naden, T Pincus, J S Smolen, E Stanislawska-Biernat, D Symmons, P P Tak, K S Upchurch, Ji í Vencovský, F Wolfe, G Hawker*



- 1589** The 2010 American College of Rheumatology/ European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I  
*J Funovits, D Aletaha, V Bykerk, B Combe, M Dougados, P Emery, D Felson, G Hawker, J M W Hazes, T Huizinga, J Kay, T K Kvien, J S Smolen, D Symmons, P P Tak, A Silman*

## Points to consider

- 1596** EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology  
*W G Dixon, L Carmona, A Finckh, M L Hetland, T K Kvien, R Landewe, J Listing, P J Nicola, U Tarq, A Zink, J Asklng*

## Review 2010

- 1603** Therapeutic opportunities in systemic lupus erythematous: state of the art and prospects for the new decade  
*G K Bertias, J E Salmon, D T Boumpas*

## Clinical and epidemiological research

- 1612** Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis  
*J Sokolove, V Strand, J D Greenberg, J R Curtis, A Kavanaugh, J M Kremer, A Anofrei, G Reed, L Calabrese, M Hooper, S Baumgartner, D E Furst; on behalf of the CORRONA Investigators*
- 1618** Ability of ultrasound imaging to detect erosions in a bone phantom model  
*J M Koski, E Alasaarela, I Soini, K Kempainen, U Hakulinen, J O Heikkinen, M S Laasanen, S Saarakkala*
- 1623** Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis  
*L H D van Tuyl, A E Voskuyl, M Boers, P Geusens, R B M Landewe, B A C Dijkmans, W F Lems*

- 1629** Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))  
*P Emery, A Deodhar, W F Rigby, J D Isaacs, B Combe, A J Racewicz, K Latinis, C Abud-Mendoza, L J Szczepański, R A Roschmann, A Chen, G K Armstrong, W Douglass, H Tyrrell*



- 1636** Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?  
*B Saleem, H Keen, V Goeb, R Parmar, S Nizam, E M A Hensor, S M Churchman, M Quinn, R Wakefield, P G Conaghan, F Ponchel, P Emery*

- 1643** Four-year follow-up of surgical versus non-surgical therapy for chronic low back pain  
*J I Brox, Ø P Nygaard, I Holm, A Keller, T Ingebrigtsen, O Reikerås*



- 1649** Effect of rheumatoid factor on mortality and coronary heart disease  
*G Tomasson, T Aspelund, T Jonsson, H Valdimarsson, D T Felson, V Gudnason*

- 1655** Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial  
*R B M Landewe, J G A Houbiers, F Van den Bosch, Joanna in't Hout, P C P M Verschuieren, J H Meijerink, F H J van den Hoogen, B A Masek, G A W Bruyn, J M G W Wouters, A E Voskuyl, J M van Laar, J J W Bijlsma, D M F M van der Heijde, F C Breedveld, L B A van de Putte, A M M Miltenburg, F de Keyser*

- 1660** Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis  
*J Franklin, T M Farragher, M Lum, E M Camacho, D Bunn, T Marshall, D P M Symmons*



### MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>

C O P E COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org.uk](http://www.publicationethics.org.uk)



When you have finished with this please recycle it

- 1665** Increased prevalence of diastolic dysfunction in rheumatoid arthritis  
*K P Liang, E Myasodova, C S Crowson, J M Davis, V L Roger, B L Karon, D D Borgeson, T M Therneau, R J Rodeheffer, S E Gabriel*
- 1671** Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT  
*A Fouque-Aubert, S Boutroy, H Marotte, N Vilayphiou, J Bacchetta, P Miossec, P D Delmas, R D Chapurlat*
- 1677** Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial  
*N Dalbeth, S Wong, G D Gamble, A Horne, B Mason, B Pool, L Fairbankes, F M McQueen, J Cornish, I R Reid, K Palmano*
- 1683** Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 \*01 and/or \*04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort  
*C Salliot, C Bombardier, A Saraux, B Combe, M Dougados*
- 1687** Lack of effect of TNF $\alpha$  blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies  
*M J L Peters, P Watt, L Cherry, P Welsh, E Henninger, B A C Dijkemans, I B McInnes, M T Nurmohamed, N Sattar*
- 1691** Demyelinating events in rheumatoid arthritis after drug exposures  
*S Bernatsky, C Renoux, S Suissa*
- 1694** Genetic variants in the prediction of rheumatoid arthritis  
*A H M van der Helm-van Mil, R E M Toes, T W J Huizinga*
- 1704** IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus  
*N Bassi, A Ghirardello, M Blank, S Zampieri, P Sarzi-Puttini, A Mantovani, Y Shoenfeld, A Doria*
- 1711** Association of variation in Fc $\gamma$  receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples  
*C McKinney, M Fanciulli, M E Merriman, A Phipps-Green, B Z Alizadeh, B P C Koeleman, N Dalbeth, P J Gow, A A Harrison, J Highton, P B Jones, L K Stamp, S Steer, P Barrera, M J H Coenen, B Franke, P L C M van Riel, T J Vyse, T J Aitman, T R D J Radstake, T R Merriman*
- 1717** Role of the cholinergic nervous system in rheumatoid arthritis: aggravation of arthritis in nicotinic acetylcholine receptor  $\alpha 7$  subunit gene knockout mice  
*M A van Maanen, S P Stoof, G J LaRosa, M J Vervoordeldonk, P P Tak*
- 1724** Gene expression profiling reveals a downregulation in immune-associated genes in patients with AS  
*R Duan, P Leo, L Bradbury, M A Brown, G Thomas*

---

## Letters

- 1730** The *PTPN22* susceptibility risk variant is not associated with the rate of joint destruction in anti-citrullinated protein antibody-positive rheumatoid arthritis  
*J A B van Nies, R Knevel, N Daha, M P M van der Linden, P K Gregersen, M Kern, S le Cessie, J J Houwing-Duistermaat, T W J Huizinga, R E M Toes, A H M van der Helm-van Mil*
- 1731** Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjögren's syndrome  
*B L Cobb, Y Fei, R Jonsson, A I Bolstad, J G Brun, M Rischmueller, S E Lester, T Witte, G Illei, M Brennan, S Bowman, K L Moser, J B Harley, A H Sawalha*

---

## Basic and translational research

- 1697** IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy  
*W A Verri Jr, F O Souto, S M Vieira, S C L Almeida, S Y Fukada, D Xu, J C Alves-Filho, T M Cunha, A T G Guerrero, R B Mattos-Guimaraes, F R Oliveira, M M Teixeira, J S Silva, I B McInnes, S H Ferreira, P Louzada-Junior, F Y Liew, F Q Cunha*
- 1733** Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs  
*F Corallini, P Secchiero, G Castellino, M Montecucco, F Trotta, G Zauli*